PDCD1 and neoplasm: ICIs block inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) and enhance anti-tumor T-cell activity providing clinical benefits in many patients with advanced cancers (1–3).